Hepatobiliary and Pancreatic Manifestations of Coronavirus Disease 2019
Coronavirus disease 2019 (COVID-19) is a new infectious disease that has spread rapidly throughout the world. The disease is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a member of the Coronaviridae family. Though the pulmonary involvement is a major cause of morbidit...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2020-03-01
|
Series: | Journal of Digestive Endoscopy |
Subjects: | |
Online Access: | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0040-1712079 |
id |
doaj-90136dda3bd341928de787d3302ef661 |
---|---|
record_format |
Article |
spelling |
doaj-90136dda3bd341928de787d3302ef6612020-11-25T03:27:07ZengThieme Medical and Scientific Publishers Pvt. Ltd.Journal of Digestive Endoscopy0976-50420976-50502020-03-011101212310.1055/s-0040-1712079Hepatobiliary and Pancreatic Manifestations of Coronavirus Disease 2019Vikas Singla0Anil Arora1Institute of Liver Gastroenterology and Pancreatico Biliary Sciences, Sir Ganga Ram Hospital, New Delhi, IndiaInstitute of Liver Gastroenterology and Pancreatico Biliary Sciences, Sir Ganga Ram Hospital, New Delhi, IndiaCoronavirus disease 2019 (COVID-19) is a new infectious disease that has spread rapidly throughout the world. The disease is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a member of the Coronaviridae family. Though the pulmonary involvement is a major cause of morbidity and mortality, involvement of the gastrointestinal tract, liver, and pancreas has been explained in these patients. The literature is rapidly changing because of influx of new information with every passage of time. The most common hepatic presentation is mild elevation of aspartate transaminase and alanine transaminase, which does not require specific treatment. Occasionally, patients can have severe liver injury. Because of underlying predisposing factors such as diabetes mellitus, hypertension, and obesity, patients with nonalcoholic liver disease may be at risk of severe disease. Patients with decompensated liver disease may also be vulnerable to severe disease. Behavior of SARS-CoV-2 in patients with chronic hepatitis B and C, autoimmune hepatitis, primary sclerosing cholangitis, and primary biliary cirrhosis is yet to be seen. The prevalence and severity of COVID-19 patients with the aforementioned diseases may be different. The effect of SARS-CoV-2 on an underlying liver disease is not known. COVID-19 may complicate the peritransplant period and throw new challenges in these patients. Drugs used to treat severe COVID-19 may cause liver injury and may have an effect on the underlying disease activity. Both hepatic and pancreatic involvement is related to the severity of COVID-19 disease. Serum amylase and lipase levels may be elevated in patients with severe COVID-19 disease. The involvement of pancreatic islet cells may lead to deranged blood sugar levels and potentially predispose to future diabetes mellitus. There are many unknown facts that will unfold with the passage of time.http://www.thieme-connect.de/DOI/DOI?10.1055/s-0040-1712079coronavirus disease 2019hepatobiliarypancreaticsevere acute respiratory syndrome coronavirus 2 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Vikas Singla Anil Arora |
spellingShingle |
Vikas Singla Anil Arora Hepatobiliary and Pancreatic Manifestations of Coronavirus Disease 2019 Journal of Digestive Endoscopy coronavirus disease 2019 hepatobiliary pancreatic severe acute respiratory syndrome coronavirus 2 |
author_facet |
Vikas Singla Anil Arora |
author_sort |
Vikas Singla |
title |
Hepatobiliary and Pancreatic Manifestations of Coronavirus Disease 2019 |
title_short |
Hepatobiliary and Pancreatic Manifestations of Coronavirus Disease 2019 |
title_full |
Hepatobiliary and Pancreatic Manifestations of Coronavirus Disease 2019 |
title_fullStr |
Hepatobiliary and Pancreatic Manifestations of Coronavirus Disease 2019 |
title_full_unstemmed |
Hepatobiliary and Pancreatic Manifestations of Coronavirus Disease 2019 |
title_sort |
hepatobiliary and pancreatic manifestations of coronavirus disease 2019 |
publisher |
Thieme Medical and Scientific Publishers Pvt. Ltd. |
series |
Journal of Digestive Endoscopy |
issn |
0976-5042 0976-5050 |
publishDate |
2020-03-01 |
description |
Coronavirus disease 2019 (COVID-19) is a new infectious disease that has spread rapidly throughout the world. The disease is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a member of the Coronaviridae family. Though the pulmonary involvement is a major cause of morbidity and mortality, involvement of the gastrointestinal tract, liver, and pancreas has been explained in these patients. The literature is rapidly changing because of influx of new information with every passage of time. The most common hepatic presentation is mild elevation of aspartate transaminase and alanine transaminase, which does not require specific treatment. Occasionally, patients can have severe liver injury. Because of underlying predisposing factors such as diabetes mellitus, hypertension, and obesity, patients with nonalcoholic liver disease may be at risk of severe disease. Patients with decompensated liver disease may also be vulnerable to severe disease. Behavior of SARS-CoV-2 in patients with chronic hepatitis B and C, autoimmune hepatitis, primary sclerosing cholangitis, and primary biliary cirrhosis is yet to be seen. The prevalence and severity of COVID-19 patients with the aforementioned diseases may be different. The effect of SARS-CoV-2 on an underlying liver disease is not known. COVID-19 may complicate the peritransplant period and throw new challenges in these patients. Drugs used to treat severe COVID-19 may cause liver injury and may have an effect on the underlying disease activity. Both hepatic and pancreatic involvement is related to the severity of COVID-19 disease. Serum amylase and lipase levels may be elevated in patients with severe COVID-19 disease. The involvement of pancreatic islet cells may lead to deranged blood sugar levels and potentially predispose to future diabetes mellitus. There are many unknown facts that will unfold with the passage of time. |
topic |
coronavirus disease 2019 hepatobiliary pancreatic severe acute respiratory syndrome coronavirus 2 |
url |
http://www.thieme-connect.de/DOI/DOI?10.1055/s-0040-1712079 |
work_keys_str_mv |
AT vikassingla hepatobiliaryandpancreaticmanifestationsofcoronavirusdisease2019 AT anilarora hepatobiliaryandpancreaticmanifestationsofcoronavirusdisease2019 |
_version_ |
1724589425906679808 |